Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip's Five Must-Know Things

Executive Summary

In this week's podcast edition of Five Must-Know Things: clinical setbacks in melanoma and prostate cancer; Chinese pharma firms face US listing pressures; Eisai hands Aduhelm to Biogen; and Scrip Asks what 2022 holds for digital and telehealth.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 18 March 2022, including: clinical setbacks in melanoma and prostate cancer; Chinese pharma firms face US listing pressures; Eisai Co., Ltd. hands Aduhelm to Biogen, Inc.; and Scrip Asks what 2022 holds for digital and telehealth.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(Also see "Nektar/BMS’s IL-2 Inhibitor Melanoma Failure Leaves Room For Other Contenders" - Scrip, 14 Mar, 2022.)

(Also see "Rare Setback For Merck & Co And AstraZeneca’s Keytruda-Lynparza Combo In Prostate Cancer" - Scrip, 16 Mar, 2022.)

(Also see "Financial Decoupling: China Biotechs Brace For Potential US Delistings, Softening Economy" - Scrip, 16 Mar, 2022.)

(Also see "Eisai Gives Full Aduhelm Responsibility To Biogen Under Amended Agreement" - Scrip, 14 Mar, 2022.)

(Also see "Scrip Asks…What Does 2022 Hold For Biopharma? Part 6: Digital And Telehealth" - Scrip, 16 Mar, 2022.)

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC146095

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel